Status:
COMPLETED
Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy
Lead Sponsor:
University of Oklahoma
Conditions:
Lymphomas
Tumors
Eligibility:
All Genders
1-21 years
Phase:
PHASE1
Brief Summary
Determine toxicity and maximum tolerated dose of escalating daily protracted irinotecan, with weekly vincristine, temozolomide and vantin; to evaluate the feasibility of repetitive cycles of this chem...
Detailed Description
Determine toxicity and maximum tolerated dose of escalating daily protracted irinotecan, with weekly vincristine, temozolomide and vantin; to evaluate the feasibility of repetitive cycles of this chem...
Eligibility Criteria
Inclusion
- Under age 21 years at time of study entry
- Malignant solid tumor, including CNS tumors and lymphomas
- Recurrent or refractory disease not amenable to other potentially curative therapies
- At least three weeks since last myelosuppressive chemotherapy \> 6 months from allogeneic stem cell transplant
- Adequate renal and hepatic function
- Adequate peripheral blood counts unless bone marrow is involved
Exclusion
- Patients with leukemia not eligible
- Patients with uncontrolled infection excluded
- Patients who have received more than 4 prior chemotherapies
- Patients who are receiving P450 enzyme-inducing anticonvulsants
- Patients who are receiving any other cancer chemotherapy or any other investigational agent
- Possible pregnancy will be excluded
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
End Date :
December 1 2007
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00222443
Start Date
September 1 2004
End Date
December 1 2007
Last Update
September 22 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oklahoma University Health Sciences Center-Jimmy Everest Center
Oklahoma City, Oklahoma, United States, 73104